Belgium Pharmaceuticals and Healthcare Report Q4 2011

Business Monitor International's (BMI) Belgium Pharmaceuticals and Healthcare Report (Q4 2011) provides industry professionals and strategists, corporate analysts, telecommunication associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Belgium's pharmaceuticals and healthcare industries.

According to BMI, the expected growth of Belgium's ageing population is to have an unprecedented effect on the provision of healthcare. The elderly require more medical check-ups and care than young people due to the increased prevalence of chronic disease with age, and therefore consume a disproportionately large share of healthcare services. The increase in healthcare spending on the ageing population will force public bodies to look for cost-containment in other areas – specifically medicines which command high proportions of healthcare budgets – which will not sit well with drugmakers.

Headline Expenditure Projections
- Pharmaceuticals: EUR4.56bn (US$6.05bn) in 2010 to EUR4.48bn (US$6.41bn) in 2011; -1.8% in local currency terms and +5.9% in US dollar terms.
- Healthcare: EUR35.75bn (US$47.42bn) in 2010 to EUR36.81bn (US$52.63bn) in 2011; +3.0% in local currency terms and +11.0% in US dollar terms.
- Medical devices: EUR7.70bn (US$10.21bn) in 2010 to EUR8.20bn (US$11.73bn) in 2011; +6.5% in local currency terms and +14.9% in US dollar terms.

Business Environment Rating: Out of a maximum 100, Belgium scored 66.0 in BMI’s Q411 Pharmaceuticals & Healthcare Business Environment Ratings (BERs), placing it fifth in the Western Europe matrix. Although growth in medicine sales is low, the country has a very large market in absolute terms. Furthermore, per-capita spending is high, there is a sizeable pensionable population and regulations are transparent.

Key Trends & Developments
Belgian pharmaceutical company UCB registered EUR1.68bn (US$2.4bn) in revenues in H111 (ended June 30 2011), up 2% year-on-year (y-o-y). During the same period, the company posted a 34% y-o-y surge in net profit to EUR199mn (US$282.2mn). The company reported a 61% y-o-y increase in combined H111 sales of Cimzia (certolizumab pegol), Vimpat (lacosamide) and Neupro (rotigotine) to EUR285mn (US$404.1mn), along with the strong performance of Keppra (levetiracetam) in the European and Japanese markets. The company expects to post revenues of about EUR3.1bn (US$4.4bn) in 2011.

BMI Economic View: The ongoing sovereign debt crises in the Eurozone will have major political and geopolitical consequences for Europe, especially if the currency bloc fragments in some way. It is no exaggeration to say that the future of the whole European 'project' is at stake. Even if the Eurozone survives in its present form, the contradictions it exposes will lead to renewed economic problems, forcing European leaders to focus on internal issues rather than increasing the continent's global influence. French and Belgian sovereign creditworthiness is coming under increasing scrutiny and fiscal consolidation may be accelerated to pre-empt a ratings downgrade.

BMI Political View: A year on from the last parliamentary election, Belgium is still without a government, surpassing all previous European political impasses and displacing Iraq as the world record holder. Moreover, with the markets fairly sanguine for now and both of the main parties showing few signs of conceding on major policy priorities, a resolution still appears some way off. Indeed, given the length of time without a government and attempts by eight successive mediators to broker a deal, it is difficult to see a solution in the near term. SHOW LESS READ MORE >

Executive Summary

SWOT Analysis
Belgium Pharmaceuticals And Healthcare Industry SWOT
Belgium Political SWOT
Belgium Economic SWOT

Pharmaceutical Business Environment Ratings
Table: Western Europe Pharmaceutical Business Environment Ratings, Q411
Rewards
Risks

Belgium – Market Summary

Regulatory Regime
Table: Applications* Received and Processed by the AFMPS/FAGG
Recent Regulatory Developments
Intellectual Property Environment
Pricing Regime
Price Cuts
Reimbursement Regime
Generic Medicines Sector
OTC Medicines Sector

Industry Trends And Developments
Epidemiology
Recent Public Health Developments
Healthcare Sector
Healthcare Financing
Healthcare Sector Developments
Medical Tourism
Research And Development Sector
Clinical Trials
Medical Device Market

Industry Forecast Scenario
Overall Market Forecast
Table: Pharmaceutical Sales Indicators 2007-2015
Key Growth Factors – Industry
Table: Health Expenditure Indicators 2007-2015
Table: Government Health Expenditure Indicators 2007-2015
Table: Private Health Expenditure Indicators 2007-2015
Key Growth Factors – Macroeconomic
Table: Belgium - Economic Activity
Prescription Drug Market Forecast
Table: Prescription Drug Sales Indicators 2007-2015
Patented Drug Market Forecast
Table: Patented Drug Sales Indicators 2007-2015
Generic Drug Market Forecast
Table: Generic Drug Sales Indicators 2007-2015
OTC Medicine Market Forecast
Table: OTC Medicine Sales Indicators 2007-2015
Medical Device Market Forecast
Table: Medical Device Sales Indicators 2007-2015
Pharmaceutical Trade Forecast
Table: Pharmaceutical Imports & Exports Indicators 2007-2015
Other Healthcare Data Forecasts
Key Risks To BMI’s Forecasts

Competitive Landscape
Pharmaceutical Industry
Recent Company Developments
Pharmaceutical Wholesale
Pharmaceutical Retail

Company Monitor
Leading Local Manufacturers
UCB Pharma
Solvay
Janssen Pharmaceutica
Omega Pharma
Galapagos
Leading Multinational Manufacturers
GlaxoSmithKline (GSK)
Pfizer
Novartis
Sanofi
Merck & Co

Country Snapshot: Belgium Demographic Data
Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education And Healthcare
Table: Education, 2002-2005
Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
Table: Employment Indicators, 2001-2006
Table: Consumer Expenditure, 2000-2012 (US$)
Table: Average Annual Wages, 2000-2012

Glossary

BMI Methodology
How We Generate Our Pharmaceutical Industry Forecasts

Pharmaceuticals Business Environment Ratings
Risk/Reward Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components

- UCB Pharma
- Solvay
- Janssen Pharmaceutica
- Omega Pharma
- Galapagos
- Leading Multinational Manufacturers
- GlaxoSmithKline (GSK)
- Pfizer
- Novartis
- Sanofi
- Merck & Co